Conditions Treated
Explore prescription medication options including semaglutide, tirzepatide, and sermorelin.
Rx required. Medications are prescribed only when appropriate.
Medication Lineup
GLP-1
GLP-1 medication for weight management support
Semaglutide is a GLP-1 receptor agonist commonly associated with medical weight-management programs and appetite-related support.
GIP / GLP-1
Dual GIP/GLP-1 medication for weight management support
Tirzepatide acts on both GIP and GLP-1 receptors and is commonly associated with medical weight-management support.
Peptide
Peptide medication for wellness and vitality support
Sermorelin is a peptide option related to growth hormone-releasing hormone pathways. It is not a GLP-1 medication.
Compare
| Medication | Category | Primary Focus | Simple Positioning |
|---|---|---|---|
| Semaglutide | GLP-1 | Weight management | Helps support appetite and weight-management goals |
| Tirzepatide | GIP/GLP-1 | Weight management | Dual-pathway option for medical weight-management support |
| Sermorelin | Peptide / GHRH analog | Wellness & vitality | Supports growth hormone signaling through the pituitary pathway |
Mechanism
Semaglutide belongs to a class of medications known as GLP-1 receptor agonists. On this page, it is described simply as a medication option commonly associated with medical weight-management programs.
Tirzepatide activates both GIP and GLP-1 receptors. FDA-approved tirzepatide weight-management labeling describes these pathways as involved in appetite and food-intake regulation.
Sermorelin works differently from GLP-1 medications. It is related to growth hormone-releasing hormone pathways and stimulates the pituitary gland to release growth hormone.
Start by medication
GLP-1 weight-management support
Start Semaglutide VisitDual GIP/GLP-1 weight-management support
Start Tirzepatide VisitPeptide wellness support
Start Sermorelin VisitFAQ
Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts on both GIP and GLP-1 receptors. Both are commonly associated with medical weight-management treatment, but they are different medications.
No. Sermorelin is not a GLP-1 medication. It is a peptide related to growth hormone-releasing hormone pathways.
Semaglutide, tirzepatide, and sermorelin are commonly offered as injectable medications.
You can select the medication you are interested in when starting your visit. Final prescribing decisions depend on clinical appropriateness.
No. Compounded medications are not FDA-approved. FDA does not verify compounded drugs for safety, effectiveness, or quality before they are marketed.
Prescription required. Medication availability may vary. Compounded medications, when prescribed, are not FDA-approved. FDA has reported concerns involving compounded semaglutide and tirzepatide, including dosing errors and adverse event reports, so dosing should always follow prescription instructions.
Start with a $49 visit and select the medication you are interested in. Prescribing decisions depend on clinical appropriateness.